Search the Newsreel

Maximus (MMS): Fuller & Thaler Asset Management discloses 5.14% ownership stake

Fuller & Thaler Asset Management, Inc. has reported a beneficial ownership stake of 5.14% in MAXIMUS, INC. (MMS), holding 2,702,709.97 shares. The firm exercises sole voting power over 2,655,263.97 shares and sole dispositive power over all 2,702,709.97 beneficially owned shares. This disclosure was made …

Replimune (NASDAQ: REPL) secures FDA accelerated approval and raises $141M

Replimune Group, Inc. reported a Q1 net loss of $69.8 million but secured FDA accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for advanced cutaneous melanoma. The company also raised $141.0 million in net proceeds from an August 2026 equity offering, extending …

Armistice Capital (IMNN) discloses 9.99% Imunon stake via Master Fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.99% of Imunon, Inc.'s common stock, totaling 450,315 shares. This stake is held through Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager and Steven Boyd as its …

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for Replimune Group, Inc. (NASDAQ: REPL) regarding a securities class action lawsuit. Shareholders who purchased REPL shares between October 20, 2025, and April 10, 2026, are encouraged to contact the firm, as the complaint alleges …

Replimune Group stock may move 5.6% on earnings release

Quantinno Capital Management LP Boosts Stock Holdings in Simulations Plus, Inc. $SLP

Quantinno Capital Management LP significantly increased its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 439.1% in the first quarter, now holding 112,259 shares valued at $1.33 million. Despite this, analyst sentiment remains cautious with an average "Reduce" rating and a $17.25 price target, even …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group Inc. (REPL) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating Replimune Group Inc. (REPL) after the FDA deemed the company's lead trial for its skin cancer drug RP1 "not interpretable," causing a significant drop in stock price. The firm is encouraging shareholders who purchased Replimune securities to …

Maximus (MMS) Flags Revenue Uncertainty, Is The Stock Still Undervalued?

Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris

Simulations Plus, Inc. announced the expiration of the Hart-Scott-Rodino (HSR) Antitrust Improvements Act waiting period, a key regulatory condition for its acquisition by Altaris, LLC. While this satisfies one major requirement, the acquisition is still contingent on shareholder approval, certain French regulatory approvals, and …

Precision Trading with Maximus Inc. (MMS) Risk Zones

The article provides a detailed analysis of Maximus Inc. (MMS) with a focus on risk zones for precision trading. It highlights weak sentiment across all horizons, supporting a short bias, and outlines specific institutional trading strategies including long, breakout, and short positions with defined …

Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results

Replimune Group (NASDAQ:REPL) reported a Q1 loss of $0.72 per share, missing analyst estimates. Despite the earnings miss and ongoing litigation, the company's shares fell by 1.4% to $14.97, and it expects to launch TUDRIQEV™ (RP1) for advanced melanoma within 60 days following FDA …

REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on

Kirby McInerney LLP has filed a securities fraud class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors who purchased securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made misleading statements regarding the Biologics License …

Simulations Plus HSR waiting period expires, Merger with Altaris remains subject to shareholder and French approvals

Simulations Plus announced that the Hart-Scott-Rodino waiting period for its merger with Altaris has expired, fulfilling a key regulatory condition. However, the merger still requires shareholder approval and certain French regulatory approvals. The transaction is anticipated to close in the second half of 2026, …

Simulations Plus (SLP) gains HSR clearance for pending Altaris acquisition

Simulations Plus (SLP) announced that it has received Hart-Scott-Rodino (HSR) antitrust clearance for its pending acquisition by Altaris affiliates. This satisfies one key regulatory condition for the merger, which is still subject to shareholder approval and certain regulatory approvals in France. The transaction is …

Maximus (MMS) Q3 2026 Earnings Call Transcript

Maximus (MMS) reported Q3 2026 earnings, meeting revenue expectations but revising full-year EPS guidance downward due to a temporary suspension of performance incentives on a VA contract. Despite this, the company projects a return to positive organic growth in its U.S. Services segment in …

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

SueWallSt is reminding shareholders of Replimune Group, Inc. (REPL) about a lead plaintiff deadline of October 5, 2026, in a securities class action lawsuit. The lawsuit alleges that Replimune made misleading statements regarding the FDA's review of its RP1 resubmission, leading to an 84% …

Replimune Group Stock Short Interest Rises to 57.95%

Replimune Group Inc. (NASDAQ:REPL) saw a significant increase in short interest during July, rising 57.95% to 5.25 million shares. This represents 14.7% of the company's shares outstanding, indicating a growing bearish sentiment among investors. The average daily trading volume suggests it would take approximately …

Maximus (NYSE:MMS) Downgraded by Zacks Research to "Strong Sell"

Zacks Research has downgraded Maximus (NYSE:MMS) to a "Strong Sell" rating, with other analysts also lowering their assessments, resulting in an overall "Reduce" rating from MarketBeat. Maximus shares opened at $54.45, near their 12-month low, and the company reported quarterly EPS that slightly beat …

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Levi & Korsinsky, LLP has issued a shareholder alert regarding a securities class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL). The lawsuit alleges that Replimune misled investors between October 20, 2025, and April 10, 2026, by claiming its RP1 FDA resubmission was on …

Replimune Group (NASDAQ:REPL) CAO Sells 7,632 Shares

Replimune Group's CAO, Andrew Schwendenman, sold 7,632 shares of the company's stock for approximately $98,987 to cover tax-withholding obligations. Despite this insider sale, Replimune has seen positive analyst sentiment and recently priced a $150 million public offering for its oncology pipeline. However, the company …

Is Maximus Stock Worth Buying as Low Valuation Meets Contract Risk?

Maximus (MMS) stock trades at a deep earnings discount, but this reflects near-term uncertainty due to federal procurement delays and contract sensitivity. While the company has a strong sales pipeline and improved liquidity, its current Zacks Rank #5 (Strong Sell) and unfavorable earnings estimate …

Replimune Group (NASDAQ:REPL) Insider Sells 11,447 Shares of Stock

Konstantinos Xynos, an insider at Replimune Group (NASDAQ:REPL), sold 11,447 shares of the company's stock for approximately $148,468 to cover tax obligations. Despite the sale, Replimune's stock has performed strongly, nearing its 52-week high, although the company reported a larger-than-expected quarterly loss. Institutional ownership …

Replimune group CEO Sushil Patel sells $510,252 in stock

Replimune Group CEO Sushil Patel sold 39,341 shares of the company's common stock for $510,252 on August 10, 2026, to cover tax withholding obligations. This sale was not discretionary and was tied to performance-based restricted stock units. The company has recently received FDA accelerated …

What happened at FDA? Replimune approval raises questions

The article discusses the accelerated approval of Replimune Group Inc.'s biologic, RP1, by the FDA for advanced melanoma, following a 10:3 advisory committee vote. This approval comes after a protracted process involving two previous rejections, political pressure, and significant debate among experts about the …

REPL Class Action Reminder - Robbins LLP Reminds Investors

Robbins LLP is reminding investors of a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL). The lawsuit alleges that Replimune misled investors about the efficacy and viability of its lead product candidate RP1, after the FDA rejected its Biologics License Application due to …

SPECTRUM AND OPTIMUM EXPAND STRATEGIC COLLABORATION TO ENHANCE LOCAL NEWS ACCESS AND ADVERTISING SOLUTIONS

Agreement Restores Spectrum News NY1 and News 12 in New York Market, Brings Spectrum News to Optimum TV Customers in Texas and North Carolina, and Expands Advertising Capabilities Through Spectrum Reach Key Takeaways The companies will restore reciprocal carriage of Spectrum News NY1 and …

Can Maximus Weather the VA Contract Hit and Rebuild Earnings Momentum?

Maximus, Inc. (MMS) faces a near-term earnings setback due to a temporary pause in performance incentives for a major Department of Veterans Affairs contract, which significantly contributed to profitability. This has led to a reduction in fiscal 2026 adjusted earnings and free cash flow …

REPL INVESTOR NOTICE: Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Robbins Geller Rudman & Dowd LLP announces a class action lawsuit against Replimune Group, Inc. (NASDAQ: REPL) for purchasers of securities between October 20, 2025, and April 10, 2026. The lawsuit alleges that Replimune made false and misleading statements regarding its Biologics License Application …

Enterprise value to revenue forward of Maximus, Inc. – NYSE:MMS

The article focuses on the enterprise value to revenue forward for Maximus, Inc. (NYSE: MMS) as presented on TradingView. It appears to be a financial data snippet, showing key information about the company's financials within the context of market data. The content is primarily …

Imunon (IMNN) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 11, 2026 at 11 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Stacy R. LindborgChief Medical Officer - Douglas V. FallerInterim Chief Financial Officer - Joshua BlacherExecutive Chairman - Michael H. TardugnoManaging Director of …

Baker Bros. Advisors (NASDAQ: REPL) details 11.8% stake and warrant buys

Baker Bros. Advisors and related entities have filed an amended beneficial ownership report for Replimune Group, Inc. common stock, revealing a beneficial ownership of 11,075,336 shares, which represents an 11.8% stake. The report also details Baker Bros.' purchase of all 2,736,340 pre-funded warrants in …

Imunon outlines OVATION 3 enrollment pace of 0.5 patients per site per month while planning early 2027 OVATION 2 data presentation

Earnings Call Insights: Imunon, Inc. (IMNN) Q2 2026 MANAGEMENT VIEW * “The second quarter marked another period of focused execution and key validation of both IMNN-001, our lead asset, and our TheraPlas platform.” (President, CEO & Director Stacy Lindborg) * “We remain very encouraged …

Imunon Q2 2026 Loss Shrinks 42.6%: -$0.54/Share vs -$0.94 Expected

Imunon, Inc. reported a Q2 2026 loss of $0.54 per share, significantly beating analyst expectations of $0.94 per share due to strong cost management. This marks a 42.6% improvement against estimates and a substantial reduction from the $2.15 loss in Q2 2025. While the …